DE60234991D1 - Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen - Google Patents

Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen

Info

Publication number
DE60234991D1
DE60234991D1 DE60234991T DE60234991T DE60234991D1 DE 60234991 D1 DE60234991 D1 DE 60234991D1 DE 60234991 T DE60234991 T DE 60234991T DE 60234991 T DE60234991 T DE 60234991T DE 60234991 D1 DE60234991 D1 DE 60234991D1
Authority
DE
Germany
Prior art keywords
transcription
expression products
detecting
slug gene
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234991T
Other languages
English (en)
Inventor
Garcia Isidro Sanchez
De Matos Alberto Orfao
Losada Jesus Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Salamanca
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Salamanca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Salamanca filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Application granted granted Critical
Publication of DE60234991D1 publication Critical patent/DE60234991D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60234991T 2001-01-23 2002-01-23 Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen Expired - Lifetime DE60234991D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100151A ES2185472B1 (es) 2001-01-23 2001-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.
PCT/ES2002/000026 WO2002059361A1 (es) 2001-01-23 2002-01-23 Empleo del gen slug o de sus productos de transcripcion o expresion en la deteccion y/o tratamiento de celulas cancerosas

Publications (1)

Publication Number Publication Date
DE60234991D1 true DE60234991D1 (de) 2010-02-25

Family

ID=8496481

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234991T Expired - Lifetime DE60234991D1 (de) 2001-01-23 2002-01-23 Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen

Country Status (7)

Country Link
US (1) US7776519B2 (de)
EP (1) EP1354962B1 (de)
JP (1) JP2004520045A (de)
AT (1) ATE454467T1 (de)
DE (1) DE60234991D1 (de)
ES (4) ES2185472B1 (de)
WO (1) WO2002059361A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2195751B1 (es) 2001-11-27 2005-04-01 Universidad De Salamanca (Otri) Mamiferos no humanos transgenicos como modelos para patologias humanas con origen en celulas stem.
ES2253028B1 (es) * 2003-05-30 2007-08-01 Universidad De Salamanca "empleo del gen slug, sus productos de transcripcion o expresion, y/o compuestos inhibidores o estimuladores de la expresion de slug para conferir radioresistencia o radioproteccion celular.
ES2301268B1 (es) * 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
EP1907533A4 (de) * 2005-06-30 2008-09-03 Whitehead Biomedical Inst Vorläuferzellen und verwendungen dafür
US20110302665A1 (en) * 2008-07-02 2011-12-08 Oktay Kirak Non-human mammals with t or b cells having predefined specificity
KR101805181B1 (ko) 2016-09-02 2017-12-07 충북대학교 산학협력단 인산화된 slug 단백질의 유사분열 세포에 대한 신규한 바이오 마커로서의 용도
WO2023126958A1 (en) * 2021-12-30 2023-07-06 Mestastop Solutions Private Limited Method for producing a spontaneous metastasis model

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
ES2242469B1 (es) 2006-07-16
ES2185472A1 (es) 2003-04-16
US7776519B2 (en) 2010-08-17
ES2185472B1 (es) 2004-10-16
US20060141454A1 (en) 2006-06-29
ATE454467T1 (de) 2010-01-15
EP1354962B1 (de) 2010-01-06
ES2339335T3 (es) 2010-05-19
JP2004520045A (ja) 2004-07-08
WO2002059361A1 (es) 2002-08-01
ES2241402A1 (es) 2005-10-16
ES2242469A1 (es) 2005-11-01
EP1354962A1 (de) 2003-10-22
ES2241402B1 (es) 2007-02-16

Similar Documents

Publication Publication Date Title
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
DE69503129D1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
ATE226643T1 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
ATE541053T1 (de) Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs
PT2380985E (pt) Células que expressam a vitamina k epóxido reductase e sua utilização
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
WO2005084109A3 (en) Cancer specific gene mh15
ATE531529T1 (de) Wertdokument, herstellung und prüfung von wertdokumenten
NO20024240D0 (no) Nye arylfruktose-1,6-bisfosfataseinhibitorer
DE602004015626D1 (de) Bei brustkrebs
WO2004047623A3 (en) Methods for identifying risk of breast cancer and treatments thereof
ATE454467T1 (de) Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen
ATE321886T1 (de) Oligonukleotide und diese enthaltende komplexe zur detektion der anwesenheit oder abwesenheit einer zielnukleinsäure in einer probe
AU2003264078A8 (en) Method for analyzing body fluids for the presence of cancer cells, use thereof, corresponding analysis kits, and use of specific active substances for treating cancer
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
DE69717840D1 (de) Nachweis und identifizierung von nicht-polio enteroviren
WO2003025141A3 (en) Genetic analysis for stratification of cancer risk
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2005024067A3 (en) Genetic analysis for stratification of breast cancer risk
DE60306865D1 (de) Detektion von Vancomycin-resistenten Enterococcus-Subspezies
NO20032391L (no) Ekspresjonsanalyse av KIAA-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
WO2002044417A3 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICA, ES

Owner name: UNIVERSIDAD DE SALAMANCA (O.T.R.I.), SALAMANCA, ES

8364 No opposition during term of opposition